1. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
by Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Constantine S. Mitsiades, Edie Weller, and Kenneth C. Anderson
Blood
Volume 123(10):
March 6, 2014
©2014 by American Society of Hematology

2. (A) PFS and (B) OS for all patients treated with lenalidomide-bortezomib-dexamethasone (censoring at time of transplant, n = 5).
(A) PFS and (B) OS for all patients treated with lenalidomide-bortezomib-dexamethasone (censoring at time of transplant, n = 5). Estimated 6-, 12-, and 24-month PFS rates were 75% (95% CI, 62-84), 36% (95% CI, 24-48), and 15% (95% CI, 7-25), respectively. Estimated 12- and 24-month OS rates were 89% (95% CI, 77-84) and 65% (95% CI, 51-76), respectively.
Paul G. Richardson et al. Blood 2014;123:
©2014 by American Society of Hematology